Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunologic diseases, complement-mediated diseases, and addictive disorders. The company's primary development programs include narsoplimab (for TA-TMA), zaltenibart (for PNH and C3G), and OMS527 (for cocaine use disorder). The commercial product OMIDRIA was sold in 2021, with results now reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Loss (Continuing Ops) | $(37.6) million | $(43.9) million |
| Net Loss (Total) | $(33.5) million | $(37.2) million |
| Net Income (Discontinued Ops) | $4.1 million | $6.7 million |
| Research & Development Expenses | $23.8 million | $26.8 million |
| Selling, General & Admin Expenses | $11.1 million | $12.3 million |
| Interest Expense | $3.7 million | $8.2 million |
| Cash Used in Operating Activities | $(35.8) million | $(41.8) million |
| Cash, Cash Equivalents & Short-Term Investments | $52.4 million | $93.8 million (Dec 31, 2024) |
| Total Debt (Carrying Value) | $185.9 million | $186.6 million (Dec 31, 2024) |
Note: Revenue from continuing operations is $0. The company has no ongoing source of revenue sufficient to cover operating costs.
Material Changes vs. Prior Period
- Net Loss Reduction: Total net loss decreased by $3.7 million compared to Q1 2024, driven primarily by a $4.6 million reduction in interest expense and lower R&D spend.
- Interest Expense: Significant decrease due to the repurchase of $118.1 million of 2026 Convertible Notes in June 2024 and favorable non-cash remeasurement adjustments on the OMIDRIA royalty obligation.
- R&D Expenses: Decreased by $3.0 million, largely due to the winding down of the IgA nephropathy program and reduced spend on the OMS1029 program, partially offset by increased costs for the PNH clinical development of zaltenibart.
- Discontinued Operations: Net income from discontinued operations (OMIDRIA royalties) decreased by $2.6 million due to lower royalties earned and reduced remeasurement adjustments.
- Liquidity: Cash and short-term investments declined from $86.7 million (short-term) at year-end 2024 to $48.2 million at March 31, 2025, reflecting operational cash burn.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Outlook
- Narsoplimab (TA-TMA): A Biologics License Application (BLA) was resubmitted to the FDA in March 2025. The FDA has assigned a target action date of September 25, 2025.
- Zaltenibart (PNH): Phase 3 clinical development was temporarily paused in Q1 2025 due to capital constraints. The company intends to restart upon securing additional capital.
- OMS527 (CUD): Enrollment for a clinical study funded by NIDA is expected to begin in 2025, with data anticipated late 2025 or early 2026.
Liquidity and Going Concern
The filing explicitly states that recurring losses and the maturity of remaining 2026 Notes on February 15, 2026, raise substantial doubt about the company's ability to continue as a going concern for one year from the issuance date. The company must maintain $25.0 million in unrestricted cash per its credit agreement covenants.
Recent Capital Actions (Post-Period)
- Convertible Note Exchange (May 14, 2025): Exchanged $70.8 million of 2026 Notes for new 2029 Notes, reducing the 2026 principal balance to $27.1 million.
- Equitization Transaction (May 12, 2025): Agreed to convert $10.0 million of 2026 Notes into common stock, further reducing the 2026 principal balance to $17.1 million upon completion.
- ATM Offering: Subsequent to March 31, 2025, the company raised $3.5 million via its At-The-Market equity facility.
Risks
- Failure to obtain FDA approval for narsoplimab by the target date.
- Inability to raise additional capital to fund operations and clinical trials.
- Restrictive covenants on the Term Loan that may limit financial flexibility.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to raise capital before the February 2026 maturity of the remaining 2026 Notes.
- FDA Decision Date: Monitor the September 25, 2025, target action date for the narsoplimab BLA resubmission.
- Debt Restructuring Impact: Confirm the final terms and dilution impact of the May 2025 note exchange and equitization transactions.
- Cash Burn Rate: Assess if the current cash balance ($52.4 million) is sufficient to fund operations through the FDA decision, given the paused Phase 3 trials.
- OMIDRIA Royalties: Review the volatility of discontinued operations income, which depends on Rayner's sales and the royalty obligation remeasurement.